The Theros Breast Cancer Index^SM separates patients into three risk groups⁵

References:
1 Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol., 24:4611-4619, 2006.
2 Goetz MP, Suman VJ, Ingle JN, et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res., 12: 2080-2087, 2006.
3 Jerevall PL, Brommesson S, Strand C, et al. Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome Breast Cancer Res Treat., 107:225-234, 2008.
4 Jansen MP, Sieuwerts AM, Look MP, et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol., 25:66266-8, 2007.
5 Ma X-J, Salunga R, Dahiya S, et al: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res., 14(9):2601-2608, 2008.
6 Page DL, Gray R, Allred DC et al. Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S- Phase Analysis by Flow Cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol 2001; 24:10-8. 7 Goldhirsch A, Coates AS, Gelber RD, et al. First – select the target: better choice of adjuvant treatment for breast cancer patients. Ann Oncol., 17:1772-1776, 2006.
8 AviaraDx, data on file.
9 Ma X-J, Erlander M, Goss P, et al. A robust five-gene RT-PCR molecular grade index stratifies recurrence risk for grade 2 tumors, predicts chemo-sensitivity and is compatible with formalin-fixed paraffin-embedded tissue. Program and abstracts of the 25th Annual Miami Breast Cancer Conference; February 20-23, 2008, Orlando, Florida.

| TOP |